Successful surgical treatment of an inflammatory lesion associated with new-onset refractory status epilepticus.

New-onset refractory status epilepticus (NORSE) has high morbidity and mortality. The authors describe the successful surgical treatment of a 56-year-old man presenting with NORSE. Magnetic resonance imaging showed a left temporal lobe lesion suspicious for a low-grade tumor, while PET imaging with the alpha[(11)C]methyl-L-tryptophan (AMT) radiotracer showed increased cortical uptake extending beyond this lesion and partly overlapping with epileptogenic cortex mapped by chronic intracranial electroencephalographic monitoring. Resection of the epileptic focus resulted in long-term seizure freedom, and the nonresected portion of the PET-documented abnormality normalized. Histopathology showed reactive gliosis and inflammatory markers in the AMT-PET-positive cortex. Molecular imaging of neuroinflammation can be instrumental in the management of NORSE by guiding placement of intracranial electrodes or assessing the extent and severity of inflammation for antiinflammatory interventions.

[1]  G. Barger,et al.  Tryptophan PET in pretreatment delineation of newly-diagnosed gliomas: MRI and histopathologic correlates , 2013, Journal of Neuro-Oncology.

[2]  M. de Curtis,et al.  Seizure‐induced brain‐borne inflammation sustains seizure recurrence and blood–brain barrier damage , 2012, Annals of neurology.

[3]  S. Dedeurwaerdere,et al.  Finding a better drug for epilepsy: Antiinflammatory targets , 2012, Epilepsia.

[4]  H. Lerche,et al.  FIRES and NORSE are distinct entities , 2012, Epilepsia.

[5]  Bertrand Tavitian,et al.  Noninvasive molecular imaging of neuroinflammation , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[6]  F. Y. Ismail,et al.  AERRPS, DESC, NORSE, FIRES: Multi‐labeling or distinct epileptic entities? , 2011, Epilepsia.

[7]  D. Chugani.  α-methyl-L-tryptophan: mechanisms for tracer localization of epileptogenic brain regions. , 2011, Biomarkers in medicine.

[8]  H. Chugani,et al.  Clinical and histopathologic correlates of 11C‐alpha‐methyl‐l‐tryptophan (AMT) PET abnormalities in children with intractable epilepsy , 2011, Epilepsia.

[9]  A. Vezzani,et al.  Acute encephalopathy with inflammation-mediated status epilepticus , 2011, The Lancet Neurology.

[10]  P. V. van Rijen,et al.  Evaluation of the innate and adaptive immunity in type I and type II focal cortical dysplasias , 2010, Epilepsia.

[11]  R. Dantzer,et al.  Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. , 2009, Journal of Neuroscience.

[12]  A. Vezzani,et al.  The role of cytokines in the pathophysiology of epilepsy , 2008, Brain, Behavior, and Immunity.

[13]  E. Aronica,et al.  Inflammatory processes in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex , 2008, Epilepsy Research.

[14]  E. Aronica,et al.  The IL-1β system in epilepsy-associated malformations of cortical development , 2006, Neurobiology of Disease.

[15]  G. Barger,et al.  In Vivo Uptake and Metabolism of α-[11C]Methyl-l-Tryptophan in Human Brain Tumors , 2006 .

[16]  H. Teoh,et al.  The NORSE (new-onset refractory status epilepticus) syndrome: defining a disease entity. , 2005, Annals of the Academy of Medicine, Singapore.

[17]  M. Baybis,et al.  Expression of ICAM-1, TNF-α, NFκB, and MAP kinase in tubers of the tuberous sclerosis complex , 2003, Neurobiology of Disease.

[18]  O. Muzik,et al.  Alpha-methyl-l-tryptophan PET detects epileptogenic cortex in children with intractable epilepsy , 2003, Neurology.

[19]  P. Blier,et al.  Effects of serotine receptors agonists, TFMPP and CGS12066B, on regional serotonin synthesis in the rat brain: an autoradiographic study , 2002, Journal of neurochemistry.

[20]  O. Muzik,et al.  Multimodality imaging for improved detection of epileptogenic foci in tuberous sclerosis complex , 2000, Neurology.

[21]  O. Muzik,et al.  α[C-11]Methyl-l-Tryptophan PET Maps Brain Serotonin Synthesis and Kynurenine Pathway Metabolism , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  O Muzik,et al.  Imaging epileptogenic tubers in children with tuberous sclerosis complex usingα‐[11C]Methyl‐L‐tryptophan positron emission tomography , 1998, Annals of neurology.

[23]  G. Byrne,et al.  Upregulation of interferon-induced indoleamine 2,3-dioxygenase in human macrophage cultures by lipopolysaccharide, muramyl tripeptide, and interleukin-1. , 1995, Cellular immunology.

[24]  Tallie Z. Baram,et al.  The role of inflammation in epilepsy , 2011, Nature Reviews Neurology.

[25]  G. Barger,et al.  In vivo uptake and metabolism of alpha-[11C]methyl-L-tryptophan in human brain tumors. , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[26]  M. Baybis,et al.  Expression of ICAM-1, TNF-alpha, NF kappa B, and MAP kinase in tubers of the tuberous sclerosis complex. , 2003, Neurobiology of disease.

[27]  M. Heyes.  The Kynurenine Pathway and Neurologic Disease , 1996 .

[28]  M. Heyes.  The kynurenine pathway and neurologic disease. Therapeutic strategies. , 1996, Advances in experimental medicine and biology.

[29]  M. Diksic,et al.  Biological model for the in vivo measurement of rate of serotonin synthesis in the brain. , 1990, Journal of neural transmission. Supplementum.